These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30123949)

  • 1. Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran.
    Lankarani KB; Ghahramani S; Moradi N; Shahraki HR; Lotfi F; Honarvar B
    Appl Health Econ Health Policy; 2018 Dec; 16(6):837-846. PubMed ID: 30123949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Willingness to pay for a quality-adjusted life-year: the individual perspective.
    Bobinac A; Van Exel NJ; Rutten FF; Brouwer WB
    Value Health; 2010 Dec; 13(8):1046-55. PubMed ID: 20825620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of Cost-Effectiveness Threshold for Health Care Interventions in Malaysia.
    Lim YW; Shafie AA; Chua GN; Ahmad Hassali MA
    Value Health; 2017 Sep; 20(8):1131-1138. PubMed ID: 28964445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey.
    Song HJ; Lee EK
    Medicine (Baltimore); 2018 Sep; 97(38):e12453. PubMed ID: 30235732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
    Nimdet K; Chaiyakunapruk N; Vichansavakul K; Ngorsuraches S
    PLoS One; 2015; 10(4):e0122760. PubMed ID: 25855971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.
    Mavrodi A; Aletras V
    Value Health Reg Issues; 2020 Sep; 22():36-43. PubMed ID: 32731168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Willingness to pay for one quality-adjusted life year in Iran.
    Moradi N; Rashidian A; Nosratnejad S; Olyaeemanesh A; Zanganeh M; Zarei L
    Cost Eff Resour Alloc; 2019; 17():4. PubMed ID: 30867654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Willingness to pay for QALY: perspectives and contexts in Japan.
    Igarashi A; Goto R; Yoneyama-Hirozane M
    J Med Econ; 2019 Oct; 22(10):1041-1046. PubMed ID: 31262236
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of the design of payment scales on the willingness to pay for health gains.
    Soeteman L; van Exel J; Bobinac A
    Eur J Health Econ; 2017 Jul; 18(6):743-760. PubMed ID: 27623946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
    Olofsson S; Norrlid H; Persson U
    J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.
    Ye Z; Abduhilil R; Huang J; Sun L
    Appl Health Econ Health Policy; 2022 Nov; 20(6):893-904. PubMed ID: 35934772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the monetary value of a Quality-Adjusted Life-Year in Quebec.
    Kouakou CRC; He J; Poder TG
    Eur J Health Econ; 2024 Jul; 25(5):787-811. PubMed ID: 37656261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.
    Moradi N; Woldemichael A; Malekian P; Rotvandi DM; Rezaei S
    Cost Eff Resour Alloc; 2020; 18():47. PubMed ID: 33110399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
    Nimdet K; Ngorsuraches S
    BMJ Open; 2015 Oct; 5(10):e008123. PubMed ID: 26438135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing WTP values of different types of QALY gain elicited from the general public.
    Pennington M; Baker R; Brouwer W; Mason H; Hansen DG; Robinson A; Donaldson C;
    Health Econ; 2015 Mar; 24(3):280-93. PubMed ID: 25625510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing preferences for prevention versus treatment using willingness to pay.
    Corso PS; Hammitt JK; Graham JD; Dicker RC; Goldie SJ
    Med Decis Making; 2002; 22(5 Suppl):S92-101. PubMed ID: 12369235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.
    Iino H; Hashiguchi M; Hori S
    PLoS One; 2022; 17(4):e0266934. PubMed ID: 35421181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. User Fees in General Practice: Willingness to Pay and Potential Substitution Patterns-Results from a Danish GP Patient Survey.
    Kronborg C; Pedersen LB; Fournaise A; Kronborg CN
    Appl Health Econ Health Policy; 2017 Oct; 15(5):615-624. PubMed ID: 28364368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.
    Byrne MM; O'malley K; Suarez-Almazor ME
    Med Decis Making; 2005; 25(6):655-66. PubMed ID: 16282216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating a WTP-based value of a QALY: the 'chained' approach.
    Robinson A; Gyrd-Hansen D; Bacon P; Baker R; Pennington M; Donaldson C;
    Soc Sci Med; 2013 Sep; 92():92-104. PubMed ID: 23849283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.